Akebia Therapeutics plans to reset Vafseo pricing after December 2026 TDAPA period following positive VOICE trial results.
Akebia Therapeutics announced plans to adjust Vafseo pricing after the December 31, 2026, Transitional Drug Add-on Payment Adjustment (TDAPA) period. The decision follows improved odds of 1.16 from the VOICE trial, supporting the drug’s potential as a standard treatment for anemia in chronic kidney disease patients on dialysis.
Management highlighted progress in advancing its kidney disease pipeline during the Q2 2026 earnings call. Vafseo’s role in treating anemia due to CKD remains a key focus, with efforts to establish it as a standard of care.
No immediate market reaction was disclosed, but the pricing reset could impact future revenue projections for the company.